These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 15337629)

  • 1. Improvement of the quality of diabetes control and decrease in the concentrations of AGE-products in patients with type 1 and insulin-treated type 2 diabetes mellitus: results from a 10 year-prospective, population-based survey on the quality of diabetes care in Germany (JEVIN).
    Schiel R; Franke S; Appel T; Voigt U; Ross IS; Kientsch-Engel R; Müller UA; Stein G
    Eur J Med Res; 2004 Aug; 9(8):391-9. PubMed ID: 15337629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement in quality of diabetes control and concentrations of AGE-products in patients with type 1 and insulin-treated type 2 diabetes mellitus studied over a period of 10 years (JEVIN).
    Schiel R; Franke S; Appel T; Voigt U; Ross IS; Kientsch-Engel R; Stein G; Müller UA
    J Diabetes Complications; 2003; 17(2):90-7. PubMed ID: 12614975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of smoking on risk factors for cardiovascular disease in patients with diabetes mellitus and renal insufficiency.
    Schiel R; Franke S; Busch M; Müller A; Fleck C; Müller UA; Braun A; Stein G
    Eur J Med Res; 2003 Jul; 8(7):283-91. PubMed ID: 12911864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced glycation end products in children with chronic renal failure and type 1 diabetes.
    Misselwitz J; Franke S; Kauf E; John U; Stein G
    Pediatr Nephrol; 2002 May; 17(5):316-21. PubMed ID: 12042886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.
    Busch M; Franke S; Wolf G; Rohde RD; Stein G;
    Nephron Clin Pract; 2008; 108(4):c291-7. PubMed ID: 18434751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Is the serum concentration of pentosidine a predictor of cardiovascular events in patients with type 2 diabetes and kidney disease?].
    Busch M; Franke S; Stein G; Wolf G;
    Dtsch Med Wochenschr; 2007 Sep; 132(36):1810-4. PubMed ID: 17726651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The advanced glycation end product N(epsilon)-carboxymethyllysine is not a predictor of cardiovascular events and renal outcomes in patients with type 2 diabetic kidney disease and hypertension.
    Busch M; Franke S; Wolf G; Brandstädt A; Ott U; Gerth J; Hunsicker LG; Stein G;
    Am J Kidney Dis; 2006 Oct; 48(4):571-9. PubMed ID: 16997053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decrease in serum levels of advanced glycation end-products by short-term lifestyle modification in non-diabetic middle-aged females.
    Yoshikawa T; Miyazaki A; Fujimoto S
    Med Sci Monit; 2009 Jun; 15(6):PH65-73. PubMed ID: 19478714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pentosidine and its deposition in renal tissue in renal transplantation.
    Yoshida K; Yoneda T; Fujimoto K; Hirao Y; Konishi N
    Transplant Proc; 2005 Dec; 37(10):4266-72. PubMed ID: 16387094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Irbesartan treatment does not influence plasma levels of the advanced glycation end products N(epsilon)(1-carboxymethyl)lysine and N(epsilon)(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial.
    Engelen L; Persson F; Ferreira I; Rossing P; Hovind P; Teerlink T; Stehouwer CD; Parving HH; Schalkwijk CG
    Nephrol Dial Transplant; 2011 Nov; 26(11):3573-7. PubMed ID: 21385863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are advanced glycation end products cardiovascular risk factors in patients with CRF?
    Stein G; Busch M; Müller A; Wendt T; Franke C; Niwa T; Franke S
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S52-6. PubMed ID: 12612953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Pentosidine: a new biomarker in diabetes mellitus complications].
    Morales S; García-Salcedo JA; Muñoz-Torres M
    Med Clin (Barc); 2011 Mar; 136(7):298-302. PubMed ID: 20226481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High serum pentosidine concentrations are associated with increased arterial stiffness and thickness in patients with type 2 diabetes.
    Yoshida N; Okumura K; Aso Y
    Metabolism; 2005 Mar; 54(3):345-50. PubMed ID: 15736112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pentosidine as a biomarker for microvascular complications in type 2 diabetic patients.
    Kerkeni M; Saïdi A; Bouzidi H; Letaief A; Ben Yahia S; Hammami M
    Diab Vasc Dis Res; 2013 May; 10(3):239-45. PubMed ID: 23091285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced glycation end-products pentosidine and N epsilon-carboxymethyllysine are elevated in serum of patients with osteoporosis.
    Hein G; Wiegand R; Lehmann G; Stein G; Franke S
    Rheumatology (Oxford); 2003 Oct; 42(10):1242-6. PubMed ID: 12777635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structured diabetes therapy and education improves the outcome of patients with insulin treated diabetes mellitus. The 10 year follow-up of a prospective, population-based survey on the quality of diabetes care (the JEVIN Trial).
    Schiel R; Voigt U; Ross IS; Braun A; Rillig A; Hunger-Dathe W; Stein G; Müller UA
    Exp Clin Endocrinol Diabetes; 2006 Jan; 114(1):18-27. PubMed ID: 16450312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Structured treatment and teaching programs and an improvement in private health care lead to a better quality of diabetes care. JEVIN, a population-based trial 1989/90 up to 1999/2000].
    Schiel R; Müller UA
    Med Klin (Munich); 2003 Jun; 98(6):303-12. PubMed ID: 12811414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trends in the management of arterial hypertension in patients with type 1 and insulin-treated type 2 diabetes mellitus over a period of 10 years (1989/1990-1994/1995). Results of the JEVIN trial.
    Schiel R; Müller UA; Beltschikow W; Stein G
    J Diabetes Complications; 2006; 20(5):273-9. PubMed ID: 16949513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of malignancies in patients with insulin-treated diabetes mellitus: results of a population-based trial with 10-year follow-up (JEVIN).
    Schiel R; Müller UA; Braun A; Stein G; Kath R
    Eur J Med Res; 2005 Aug; 10(8):339-44. PubMed ID: 16131475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated serum levels of AGEs, sRAGE, and pentosidine in Tunisian patients with severity of diabetic retinopathy.
    Kerkeni M; Saïdi A; Bouzidi H; Ben Yahya S; Hammami M
    Microvasc Res; 2012 Nov; 84(3):378-83. PubMed ID: 22835520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.